Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...

Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate ...

The European Union (EU) is actively courting biotech for economic growth and has launched several initiatives to attract ...

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...

Changing healthcare provider (HCP) and patient expectations have disrupted conventional customer engagement methods across the entire healthcare ecosystem. The traditional reach and frequency model ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.